RARECAREnet Event: Rare Cancers In Belgium
An ECPC, RARECAREnet and Belgian Cancer Registry event: Quality of care for rare cancers in Belgium, 16 April 2015
News
Bortezomib & first-line treatment in mantle-cell lymphoma
Bortezomib based therapy effective in patients with newly diagnosed mantle-cell lymphoma, an incurable, aggressive haematological malignancy
Brussels Event Mar 2015
Save the date: Workshop in Brussels on March 24 2015 to explore how European Reference Networks (ERNs) can help find solutions for the unique needs of rare cancer patients
Rare Disease Day 2015
Rare Disease Day 2015 seeks to raise awareness of the challenges faced by patients and their families
Interview with RCE Chair Paolo Casali in Innovations in Oncology Report
'Success with orphan drugs needn't be rare'
FDA Approves Lenvatinib for Differentiated Thyroid Cancer Refractory to Iodine-131
Offering a new treatment paradigm for a group of patients for whom, until recently, there has been no new effective treatment since the 1940s.
EORTC opens trial for patients with high grade undifferentiated uterine sarcoma, a rare cancer
The trial plans to assess the efficacy of maintenance treatment with cabozantinib
Position paper from the Chordoma Global Consensus Group published in The Lancet Oncology
Building a global consensus approach to chordoma: a position paper from the medical and patient community
EURODIS: What Is a European Reference Network?
An article from EURODIS explaining why we need ERNs
Press Release: Specific clinical trial methodology needed for rare cancers
A consensus paper published in Annals of Oncology by Rare Cancers Europe (RCE), calls for new methodologies to be applied to clinical studies in rare cancers